A Randomized, Double-Blind, Double-Dummy Study to Evaluate the Intranasal Human Abuse Potential and Pharmacokinetics of a Novel Extended-Release Abuse-Deterrent Formulation of Oxycodone.

Journal: Pain medicine (Malden, Mass.)

PMID: 26814256

Abstract

OBJECTIVE: Evaluate the human abuse potential (HAP) of an experimental, microsphere-in-capsule formulation of extended-release oxycodone (oxycodone DETERx®) (herein "DETERx").

Authors

Lynn R Webster

*Early Development Services, Scientific Affairs, PRA Health Sciences, Salt Lake City, Utah, USA; WebsterLynn@prahs.com.
Ernest A Kopecky

Clinical Development and.
Michael D Smith

*Early Development Services, Scientific Affairs, PRA Health Sciences, Salt Lake City, Utah, USA;
Alison B Fleming

Product Development, Collegium Pharmaceutical Inc., Canton, Massachusetts, USA.

Keywords

Administration, Intranasal Adult Analgesics, Opioid Cross-Over Studies Delayed-Action Preparations Double-Blind Method Female Humans Male Middle Aged Opioid-Related Disorders Oxycodone Young Adult

External Resources

View on PubMed Access via DOI PubMed (26814256)

A Randomized, Double-Blind, Double-Dummy Study to Evaluate the Intranasal Human Abuse Potential and Pharmacokinetics of a Novel Extended-Release Abuse-Deterrent Formulation of Oxycodone.

Abstract

Authors

Keywords

External Resources

Popular Topics

Recent Journals